Metformin and doxycycline
Phase 3Small molecule
Metformin and doxycycline is one of 51 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Femara
NovartisApproved
Actos
TakedaApproved
Myrbetriq
AstellasApproved
Daliresp
AstraZenecaApproved
Evista
Eli LillyApproved
Onglyza
AstraZenecaApproved
Calciferol
Jazz PharmaceuticalsApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polycystic Ovary Syndrome1 trial
Semaglutide in Women With Polycystic Ovary Syndrome and Obesity
Recruiting·—·Phase 2/3·NCT06896981·30 enrolled
Acne Vulgaris1 trial
Comparative Study of Metformin Versus Doxycycline in Moderate to Severe Adult Acne Vulgaris Patients.
Unknown status·—·Phase 2·NCT06252194·120 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Metformin and doxycycline. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details